“…The PEN-NS rates among PCV13 STs from both age groups rose to 37.7–39.9% from 2009 to 2011, decreasing in subsequent years (2012–2017) to 11.8–16.4% (Figure 1). Similar results were observed for PEN-NS rates against the STs included in PCV13 but not PCV7 (Figure 2). …”
Enlace del recurso
Enlace del recurso

“…We evaluated the in vitro activity of these 5 BL/BLIs and comparators against P. aeruginosa (PSA) causing cystic fibrosis (CF) pulmonary exacerbation. [Figure: see text] [Figure: see text] METHODS: 383 PSA isolates (1/patient) were recovered from 35 medical centers in the US (n=187) and 12 European countries (EU; n=196) in 2018-2021 and susceptibility tested by CLSI broth microdilution method. …”
Enlace del recurso
Enlace del recurso

“…The activity of PLZ (99.3% susceptible [S]) was comparable to that of colistin and higher than other comparators against ESBL isolates (Figure). AMK inhibited 96.4% of the isolates and GEN and TOB inhibited 57.9% and 43.5%, respectively. …”
Enlace del recurso
Enlace del recurso

“…The proportion of IPD and N-INV pneumonia due to vaccine serotypes decreased consistently and monotonically until 2014 and then plateaued (Figure 1). CONCLUSION: We found a strong correlation between databases (SENTRY and ABC) and between INV and N-INV pneumococcal disease in the proportion of disease due to PCV13 types. …”
Enlace del recurso
Enlace del recurso

“…RESULTS: All BLs had limited activity against CRE isolates (MIC(50/90), ≥32/ >32 mg/L) and QPX lowered the MIC for all agents (figure). Against 157 isolates carrying serine-carbapenemase (SCarb) genes (153 KPC-producers), MEM or ETP plus QPX at fixed 4 or 8 mg/L displayed MIC(50) at ≤ 0.03 mg/L and MIC(90) ranging from 0.12 to 0.5 mg/L. …”
Enlace del recurso
Enlace del recurso

“…This study reports on the in vitro activity of gepotidacin and other oral antibiotics when tested against contemporary Escherichia coli and Staphylococcus saprophyticus clinical isolates collected from patients with UTIs for a gepotidacin uUTI global surveillance study. [Figure: see text] METHODS: A total of 1,001 E. coli and 92 S. saprophyticus isolates were collected during 2022 from 45 medical centers located within the United States. …”
Enlace del recurso
Enlace del recurso

“…RESULTS: Overall, ORI showed similar MIC(50) (0.03 mg/L) and MIC(90) results (0.06 mg/L) against MRSA and MSSA (figure) and the SA EC subset (41.7% MRSA; data not shown). …”
Enlace del recurso
Enlace del recurso

“…We evaluated the activity of ceftazidime-avibactam (CAZ-AVI) and aztreonam-avibactam (ATM-AVI) and comparators against common BLs detected in US hospitals. [Figure: see text] METHODS: A total of 21,853 Enterobacterales (ENT) isolates collected during 2020–2021 were susceptibility (S) tested by reference broth microdilution methods. …”
Enlace del recurso
Enlace del recurso

“…As aminoglycosides are frequently used to treat infections caused by multidrug-resistant (MDR) and carbapenem-resistant Enterobacterales (CRE), we evaluated the activity of plazomicin and the impact of CLSI breakpoint changes on the susceptibility rates of Enterobacterales collected from US medical centers. [Figure: see text] METHODS: 5,725 Enterobacterales isolates were consecutively collected (1/patient) from 36 US medical centers in 2020–2022 and susceptibility tested by broth microdilution against amikacin, gentamicin, tobramycin, and plazomicin. …”
Enlace del recurso
Enlace del recurso

“…Activity of sulbactam-durlobactam (fixed 4 mg/L), antibacterial combinations, and comparators against a set of 66 A. baumannii-calcoaceticus species complex isolates [Figure: see text] METHODS: Bacterial isolates consisted of 41 ACB isolates from the Centers for Disease Control and Prevention Antimicrobial Resistance Bank and 25 molecularly characterized cefiderocol-resistant ACB clinical isolates from the SENTRY Antimicrobial Surveillance Program. …”
Enlace del recurso
Enlace del recurso

“…This study evaluated the activity of BPR and comparator agents against E. faecalis isolated from patients hospitalized in US medical centers. [Figure: see text] METHODS: A total of 1,834 E. faecalis isolated from 34 US medical centers (2016–2020) were included. …”
Enlace del recurso
Enlace del recurso

“…The activity of OMC and comparators was evaluated against S. pneumoniae (SPN) from the USA, as well as the resistance (R) mechanisms in tetracycline (TET) non-susceptible (NS) SPN. [Figure: see text] METHODS: 1,038 SPN from 31 USA centers (2019-2021) were tested by CLSI broth microdilution. …”
Enlace del recurso
Enlace del recurso

“…We evaluated the frequency and antimicrobial susceptibility of Gram-negative bacteria (GNB) causing pneumonia in US hospitals. [Figure: see text] METHODS: Bacterial isolates were consecutively collected (1/patient) from patients hospitalized with pneumonia and the susceptibility of GNBs (3,911 Enterobacterales [ENT] and 2,753 non-fermenters) was evaluated by broth microdilution. …”
Enlace del recurso
Enlace del recurso

“…This methodology can be expanded to other species. Figure 1 [Image: see text] DISCLOSURES: Rodrigo E. …”
Enlace del recurso
Enlace del recurso

“…The in vitro activity of oritavancin (ORI) and comparators was evaluated against CoNS causing BSI in US medical centers. [Figure: see text] METHODS: 587 CoNS isolates (1/patient) were consecutively collected in 30 US centers in 2017-2019. …”
Enlace del recurso
Enlace del recurso

“…Activity of cefiderocol and comparator agents against Achromobacter and Burkholderia Isolates [Figure: see text] METHODS: Minimum inhibitory concentrations (MICs) were determined according to CLSI guidelines against 167 Achromobacter and 160 Burkholderia cepacia species complex isolates, using broth microdilution with cation-adjusted Mueller-Hinton broth (CAMHB) for comparator agents and iron-depleted CAMHB for CFDC. …”
Enlace del recurso
Enlace del recurso

“…We evaluated the activities of ATM-AVI, ceftazidime-avibactam (CAZ-AVI), meropenem-vaborbactam (MEM-VAB), and comparators against ENT isolated from patients with bloodstream infections (BSIs). [Figure: see text] METHODS: 4,802 ENT were consecutively collected (1/patient) from 72 US medical centers in 2020–2022 and susceptibility tested by CLSI broth microdilution method. …”
Enlace del recurso
Enlace del recurso

“…The activity of ORI and comparators against Staphylococcus aureus (SA), β-hemolytic streptococci (BHS), and Viridans group Streptococcus (VGS) causing SSSI in US medical centers in 2022 and 2017–2019 was compared. [Figure: see text] METHODS: 6,110 SSSI pathogens, including 705/4,550 SA from 2022/2017–2019, 158/613 BHS, and 27/57 VHS isolates, respectively, were collected (1/patient) from 33 US medical centers. …”
Enlace del recurso
Enlace del recurso

“…CFDC and comparator activities were evaluated against resistant and molecularly characterized P. aeruginosa (PSA) and A. baumannii-calcoaceticus complex (ABC) as part of the SENTRY Antimicrobial Surveillance Program. [Figure: see text] METHODS: 3,384 PSA and 1,186 Acinetobacter spp. (979 ABC) were consecutively collected from 64 US sites in 2020–2022. …”
Enlace del recurso
Enlace del recurso

“…The in vitro activity of CFDC and comparator agents was evaluated against Enterobacterales isolates collected during 2020-2022 in the SENTRY Antimicrobial Surveillance Program, stratified by infection type. [Figure: see text] METHODS: 11,805 Enterobacterales from the USA were tested for susceptibility (%S) using CLSI broth microdilution with cation-adjusted Mueller-Hinton broth (CAMHB) or iron-depleted CAMHB for CFDC. …”
Enlace del recurso
Enlace del recurso